Hefei Lifeon Pharmaceutical (003020) Stock Overview

Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients. It operates through Pharmaceutical Industry, Pharmaceutical Wholesale and Distribution, and Pharmaceutical Retail Business segments. The company offers active pharmaceutical ingredients, which include nifedipine, paliperidone, prilocaine, methylphenidate hydrochloride, dimercaptosuccinic acid, doxazosin mesylate, paeonol, urea, felodipine, and troxerutin; and medical preparations, such as osmotic pump preparations, central nervous systems, Chinese patent medicines, eye drops, external use, and general oral medicines. In addition, it provides medical intermediates, including 3-methoxy-1 propanethiol, mercaptosuccinic acid, domiphene, sodium dimercaptosulfonate, 3-mercapto-1-propanol, paeonol, sodium paeonol sulfonate, methyl 2,3-dichlorobenzylidene acetoacetate, n-[(1,4-benzodioxan-2-yl) carbonyl piperazine hydrochloride, alogliptin benzoate, roflumilast, and zofenopril calcium; plant extract products, such as clove oil and campanula extracts; and pieces that consist of poria decoction, astragalus, honeysuckle, rose, and phellinus decoction. Further, the company offers central nervous system drugs, cardiovascular drugs, digestive system drugs, ophthalmic drugs, external skin drugs and other fields. Hefei Lifeon Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Hefei, China.